Tuberculosis, Pulmonary — Azacytidine During Anti-tuberculosis Therapy
Citation(s)
Ahn E, Youngblood B, Lee J, Lee J, Sarkar S, Ahmed R Demethylation of the PD-1 Promoter Is Imprinted during the Effector Phase of CD8 T Cell Exhaustion. J Virol. 2016 Sep 12;90(19):8934-46. doi: 10.1128/JVI.00798-16. Print 2016 Oct 1.
Botha T, Ryffel B Reactivation of latent tuberculosis infection in TNF-deficient mice. J Immunol. 2003 Sep 15;171(6):3110-8. doi: 10.4049/jimmunol.171.6.3110.
Bustamante J, Boisson-Dupuis S, Abel L, Casanova JL Mendelian susceptibility to mycobacterial disease: genetic, immunological, and clinical features of inborn errors of IFN-gamma immunity. Semin Immunol. 2014 Dec;26(6):454-70. doi: 10.1016/j.smim.2014.09.008. Epub 2014 Oct 26.
Carson WF, Cavassani KA, Dou Y, Kunkel SL Epigenetic regulation of immune cell functions during post-septic immunosuppression. Epigenetics. 2011 Mar;6(3):273-83. doi: 10.4161/epi.6.3.14017. Epub 2011 Mar 1.
DuPage M, Bluestone JA Harnessing the plasticity of CD4(+) T cells to treat immune-mediated disease. Nat Rev Immunol. 2016 Mar;16(3):149-63. doi: 10.1038/nri.2015.18. Epub 2016 Feb 15.
Durzynska J, Lesniewicz K, Poreba E Human papillomaviruses in epigenetic regulations. Mutat Res Rev Mutat Res. 2017 Apr-Jun;772:36-50. doi: 10.1016/j.mrrev.2016.09.006. Epub 2016 Sep 19.
Ehlers S Role of tumour necrosis factor (TNF) in host defence against tuberculosis: implications for immunotherapies targeting TNF. Ann Rheum Dis. 2003 Nov;62 Suppl 2(Suppl 2):ii37-42. doi: 10.1136/ard.62.suppl_2.ii37.
Singal R, Ramachandran K, Gordian E, Quintero C, Zhao W, Reis IM Phase I/II study of azacitidine, docetaxel, and prednisone in patients with metastatic castration-resistant prostate cancer previously treated with docetaxel-based therapy. Clin Genitourin Cancer. 2015 Feb;13(1):22-31. doi: 10.1016/j.clgc.2014.07.008. Epub 2014 Aug 1.
Starke JR Mortality in childhood tuberculosis: has there been progress? Lancet Infect Dis. 2017 Mar;17(3):239-241. doi: 10.1016/S1473-3099(16)30537-0. Epub 2016 Dec 8. No abstract available.
Tough DF, Tak PP, Tarakhovsky A, Prinjha RK Epigenetic drug discovery: breaking through the immune barrier. Nat Rev Drug Discov. 2016 Dec;15(12):835-853. doi: 10.1038/nrd.2016.185. Epub 2016 Oct 21.
Tsai PC, Bell JT Power and sample size estimation for epigenome-wide association scans to detect differential DNA methylation. Int J Epidemiol. 2015 Aug;44(4):1429-1441. doi: 10.1093/ije/dyv041. Epub 2015 May 13.
van der Walt M, Lancaster J, Shean K Tuberculosis Case Fatality and Other Causes of Death among Multidrug-Resistant Tuberculosis Patients in a High HIV Prevalence Setting, 2000-2008, South Africa. PLoS One. 2016 Mar 7;11(3):e0144249. doi: 10.1371/journal.pone.0144249. eCollection 2016.
Wang L, Amoozgar Z, Huang J, Saleh MH, Xing D, Orsulic S, Goldberg MS Decitabine Enhances Lymphocyte Migration and Function and Synergizes with CTLA-4 Blockade in a Murine Ovarian Cancer Model. Cancer Immunol Res. 2015 Sep;3(9):1030-41. doi: 10.1158/2326-6066.CIR-15-0073. Epub 2015 Jun 8.
Wen H, Dou Y, Hogaboam CM, Kunkel SL Epigenetic regulation of dendritic cell-derived interleukin-12 facilitates immunosuppression after a severe innate immune response. Blood. 2008 Feb 15;111(4):1797-804. doi: 10.1182/blood-2007-08-106443. Epub 2007 Nov 30.
Wherry EJ, Kurachi M Molecular and cellular insights into T cell exhaustion. Nat Rev Immunol. 2015 Aug;15(8):486-99. doi: 10.1038/nri3862.
Youngblood B, Reich NO The early expressed HIV-1 genes regulate DNMT1 expression. Epigenetics. 2008 May-Jun;3(3):149-56. doi: 10.4161/epi.3.3.6372. Epub 2008 May 31.
Zumla A, Rao M, Dodoo E, Maeurer M Potential of immunomodulatory agents as adjunct host-directed therapies for multidrug-resistant tuberculosis. BMC Med. 2016 Jun 15;14:89. doi: 10.1186/s12916-016-0635-1.
Phase 1b/2a Safety and Immunogenicity of the DNMT Inhibitor Azacitidine During Anti-Tuberculosis Therapy
Interventional studies are often prospective and are specifically tailored to evaluate direct impacts of treatment or preventive measures on disease.
Observational studies are often retrospective and are used to assess potential causation in exposure-outcome relationships and therefore influence preventive methods.
Expanded access is a means by which manufacturers make investigational new drugs available, under certain circumstances, to treat a patient(s) with a serious disease or condition who cannot participate in a controlled clinical trial.
Clinical trials are conducted in a series of steps, called phases - each phase is designed to answer a separate research question.
Phase 1: Researchers test a new drug or treatment in a small group of people for the first time to evaluate its safety, determine a safe dosage range, and identify side effects.
Phase 2: The drug or treatment is given to a larger group of people to see if it is effective and to further evaluate its safety.
Phase 3: The drug or treatment is given to large groups of people to confirm its effectiveness, monitor side effects, compare it to commonly used treatments, and collect information that will allow the drug or treatment to be used safely.
Phase 4: Studies are done after the drug or treatment has been marketed to gather information on the drug's effect in various populations and any side effects associated with long-term use.